Found: Other Guidance • European Respiratory Society (ERS) .
Jul. 24 2024
Source Page: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosisFound: Appendix C National I nstitute for Health and Care Excellence Matrix for the single technology
Jun. 06 2024
Source Page: Pneumonia: diagnosis and management (update)Found: Job Title, Organisation Comment Chair Chair Tessa Lewis GP (locum): self employed & Oxford Health
Found: Cross -Party Group Annual Return Name of Cross -Party Group Cross -Party Group on Lung Health
Jul. 16 2024
Source Page: Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266Found: All rights reserved. 1 of 3 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 September 2024 to Question 3791 on Respiratory Syncytial Virus: Vaccination, whether he has received any advice from the Joint Committee on Vaccination and Immunisation on whether that vaccine should be extended to those children over one year old with spinal muscular atrophy type 1.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Joint Committee on Vaccination and Immunisation (JCVI) has not provided advice on whether the respiratory syncytial virus (RSV) vaccine should be extended to children over the age of one year with spinal muscular atrophy type 1.
The JCVI considered a range of evidence in advising who should be offered an immunisation, including the impact of the vaccine in different age groups, as well as the capacity of the National Health Service to deliver the programme alongside other important healthcare priorities.
The vaccine for the national RSV programmes, Pfizer’s Abrysvo, is approved only for use in pregnant women, for infant protection, and older adults, following clinical trials in these groups. The JCVI has not provided advice on other groups, as the analysis that informed their advice looked at burden by age.
In June 2023, the JCVI advised that existing infant risk groups eligible for RSV monoclonal antibody immunisation should preferentially be protected with nirsevimab over palivizumab. While children over the age of one year with spinal muscular atrophy type 1 are not currently in the eligible cohort, the JCVI’s advice is that NHS specialised commissioning should work within the existing guidance on preventative treatment for children considered to be at equivalent risk based on clinical judgment. The JCVI may provide further advice on the use of RSV monoclonal antibody immunisation in risk groups outside of the current recommendations in the future.
Asked by: Sarah Coombes (Labour - West Bromwich)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether improving respiratory health will be central to the new NHS 10-year plan.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan will consider the change needed to meet the three health mission goals: a fairer system where everyone lives well for longer; a National Health Service that is there when people need it; and fewer lives lost to the biggest killers. We will carefully be considering policies with input from the public, patients, health staff, and our stakeholders as we develop the plan.
Asked by: Lord Blunkett (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what percentage of primary care practices in Sheffield did not have availability of the respiratory syncytial virus vaccine by 20 September.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Respiratory syncytial virus (RSV) vaccination programmes for pregnant women to protect newborns and adults aged between 75 and 79 years old began in England on 1 September 2024.
Supplies of RSV vaccines were available for all general practices (GPs) and maternity services in England to order, including those in the South Yorkshire Integrated Care Board area, from 1 August 2024, to allow pre-positioning of vaccine stock in the National Health Service in advance of the national programmes going live in September.
The South Yorkshire Integrated Care Board supported the national timelines and promoted the programmes extensively, with GPs and maternity services administering RSV vaccines to eligible groups from the 1 September. While a small number of GPs in Sheffield have experienced delays in starting the RSV programmes, all have now placed supply orders and are offering bookings for those who are eligible to get vaccinated.
Found: Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Asked by: Lord Blunkett (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government at what point in September the respiratory syncytial virus vaccine for infants and those aged 75 to 80 was made available in the South Yorkshire Integrated Care Board area.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Respiratory syncytial virus (RSV) vaccination programmes for pregnant women to protect newborns and adults aged between 75 and 79 years old began in England on 1 September 2024.
Supplies of RSV vaccines were available for all general practices (GPs) and maternity services in England to order, including those in the South Yorkshire Integrated Care Board area, from 1 August 2024, to allow pre-positioning of vaccine stock in the National Health Service in advance of the national programmes going live in September.
The South Yorkshire Integrated Care Board supported the national timelines and promoted the programmes extensively, with GPs and maternity services administering RSV vaccines to eligible groups from the 1 September. While a small number of GPs in Sheffield have experienced delays in starting the RSV programmes, all have now placed supply orders and are offering bookings for those who are eligible to get vaccinated.